Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method.
Saved in:
| Title: | Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. |
|---|---|
| Authors: | Dou Y; School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing 100084, China., Xu K; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China., Deng YQ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China., Jia Z; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China., Lan J; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China., Xu X; Vazyme Biotech Co., Ltd., Nanjing, China., Zhang G; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China., Cao T; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China., Liu P; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China., Wang X; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China., Wang X; Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China., Xu L; Vazyme Biotech Co., Ltd., Nanjing, China., Du P; Vazyme Biotech Co., Ltd., Nanjing, China., Qin CF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China., Liu H; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China., Li Y; Shanxi Provincial Key Laboratory of Kidney Disease, The Fifth Hospital of Shanxi Medical University, Taiyuan 030012, China., Wu G; NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China., Wang K; National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China., Lu B; School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing 100084, China. |
| Source: | Antibody therapeutics [Antib Ther] 2023 Feb 17; Vol. 6 (2), pp. 76-86. Date of Electronic Publication: 2023 Feb 17 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 101730822 Publication Model: eCollection Cited Medium: Internet ISSN: 2516-4236 (Electronic) Linking ISSN: 25164236 NLM ISO Abbreviation: Antib Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2516-4236 |
|---|---|
| DOI: | 10.1093/abt/tbad002 |
